Porzsolt, F. and Otto, A. M. and Trauschel, B. and Buck, C. and Wawer, A. W. and Schönenberger, Helmut (1989) Rationale for combining tamoxifen and interferon in the treatment of advanced breast cancer. Journal of cancer research and clinical oncology 115 (5), pp. 465-469.
Full text not available from this repository.
Several investigators have discussed the possible combination of tamoxifen and interferon (IFN) in the treatment of breast cancer patients. The rationale in combining these drugs is that IFN induces the expression of estrogen receptors and therefore increases the sensitivity of breast cancer cells toward the growth-inhibitory activity of tamoxifen. In this paper we review the literature on the ...
Export bibliographical data
|Additional Information (public):||GERMANY, WEST: Germany, Federal Republic of 10540-29-1 (Tamoxifen); 9008-11-1 (Interferons)|
|Institutions:||Chemistry and Pharmacy > Institute of Pharmacy > Alumni or Retired Professors > Prof. Schönenberger|
|Keywords:||Antineoplastic Combined Chemotherapy Protocols: PD, pharmacology *Antineoplastic Combined Chemotherapy Protocols: TU, therapeutic use Breast Neoplasms: AN, analysis *Breast Neoplasms: DT, drug therapy Breast Neoplasms: PA, pathology Humans *Interferons: AD, administration & dosage Receptors, Estrogen: AN, analysis *Tamoxifen: AD, administration & dosage Tumor Cells, Cultured: DE, drug effects 0 (Receptors, Estrogen)|
|Dewey Decimal Classification:||500 Science > 540 Chemistry & allied sciences|
|Refereed:||Yes, this version has been refereed|
|Created at the University of Regensburg:||Yes|
|Deposited on:||12 Nov 2010 07:30|
|Last modified:||12 Nov 2010 07:30|